Development Of a Concentrated Tranexamic Acid (TXA) Intramuscular Injection

This award is for the development of a concentrated Tranexamic Acid (TXA) Intramuscular Injection.  The Government seeks this development in order to receive FDA approval for the concentrated IM TXA formulation that can be delivered in a pref-filled syringe or a dedicated autoinjector.

This contract action was awarded competitively as a Cost Share Contract.  A Cost Share Contract was used in accordance with FAR 35.006 (c) due to an absence of precise specifications and difficulties in estimating costs with accuracy.